We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Shares of Houston-based Bellicum Pharmaceuticals plunged more than 48 percent in aftermarket trading after the company announced FDA slapped a clinical hold on its lead cell therapy product after three cases of encephalopathy were reported.